OXBOW Equities Corp.

OXBOW Equities Corp.

January 07, 2005 09:29 ET

OXBOW: MonoGen Files a PMA Submission with the FDA for its MonoPrep® Pap Test




JANUARY 7, 2005 - 09:29 ET

OXBOW: MonoGen Files a PMA Submission with the FDA for
its MonoPrep® Pap Test

MONTREAL, QUEBEC--(CCNMatthews - Jan. 7, 2005) - Oxbow Equities Corp.
("Oxbow", TSX:XBO) today announced that its 47% owned Greater Chicago
area investee company MonoGen, Inc. ("MonoGen") has completed its
clinical trial of its MonoPrep® Pap Test and filed a PMA submission to
the U.S. Food and Drug Administration (FDA).

Oxbow CEO Andre Denis commented: "We are pleased that MonoGen has
reached this major milestone. The clinical trial for its first
diagnostic test was conducted at many centers. We look forward to a
timely review by the FDA."

MonoGen, Inc. (http://www.monogen.com) of Vernon Hills, Illinois, is a
privately held corporation focused on providing products that automate
anatomic and molecular pathology laboratories, particularly the process
of preparing and analyzing cellular specimens. MonoGen's products have
been designed not only to improve cytology test preparations and
analyses, but also to serve as a universal platform for more sensitive
and effective tests for non-gynecological cancers. MonoGen's intrinsic
value is protected by a broad-patent portfolio in specimen preparation,
molecular diagnostics, and imaging and information systems.

Oxbow is a publicly traded venture management corporation whose assets
are substantially comprised of two U.S. private medical device
companies, Mission Medical, Inc. and MonoGen, Inc., in which Oxbow is
the largest stockholder. Oxbow is an active investor providing its
investee companies with strategic direction and management in addition
to capital.

The common shares of Oxbow are listed for trading on the Toronto Stock
Exchange under the trading symbol "XBO".

This news release contains forward-looking statements within the meaning
of the "safe harbor" provisions of the U.S. Private Securities
Litigation Reform Act of 1995. These forward-looking statements are
subject to risks and uncertainties and other factors that may cause
Oxbow's results to differ materially from expectations. These include
risks relating to market fluctuations, investee performance and other
risks. These forward-looking statements speak only as of the date
hereof. Oxbow disclaims any intent or obligation to update these
forward-looking statements.

Not for Distribution in the United States


Contact Information

    Oxbow Equities Corp.
    Mr. Andre Denis
    President and Chief Executive Officer
    (514) 286-0999, ext. 224
    (514) 286-3777 (FAX)